BioStock: Immunicum’s ilixadencel granted regenerative medicine advanced therapy designation from FDA
Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel. BioStock reached out to Immunicum’s COO Sijme Zeilemaker to learn more about the news and what it means for ilixadencel moving forward.
Read the full interview with Sijme Zeilemaker at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se